Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 1,317 shares, a decline of 76.6% from the May 14th total of 5,626 shares. Based on an average trading volume of 26,884 shares, the short-interest ratio is presently 0.0 days.
Sunshine Biopharma Stock Down 11.5%
NASDAQ SBFMW opened at $0.03 on Wednesday. Sunshine Biopharma has a 52-week low of $0.03 and a 52-week high of $0.65. The company has a fifty day moving average of $0.12 and a 200-day moving average of $0.15.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Read More
- Five stocks we like better than Sunshine Biopharma
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
